Merck KGaA agrees to buy Rapid Micro Biosystems as maker pulls 2026 outlook
The US maker of rapid microbial testing instruments disclosed the takeover pact alongside quarterly sales of $9.5m, but gave no price, timetable or conditions.
Rapid Micro Biosystems has signed a definitive agreement to be acquired by Merck KGaA of Darmstadt, Germany, the company said on 16 November 2026. The purchase is to be structured as a tender offer to shareholders, which had not been launched at the time of the announcement.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Rapid Micro Biosystems, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.